Tocilizumab-induced Transaminitis in a Seropositive Rheumatoid Arthritis Patient with Macrophage Activation Syndrome / 이화의대지
The Ewha Medical Journal
;
: 23-27, 2016.
Artículo
en Inglés
| WPRIM
| ID: wpr-147090
ABSTRACT
As a new humanized monoclonal antibody against the interleukin-6 receptor, tocilizumab is currently used for the treatment of rheumatoid arthritis (RA) patients. Tocilizumab was reported to provoke drug-related liver toxicity, although there have been no reports on significant liver toxicity from tocilizumab in Korean patients with RA to date. Here, we describe the first case of tocilizumab-related liver toxicity in a patient with complicated RA, accompanied with macrophage activation syndrome, who had received tacrolimus and prednisolone and in whom both conventional disease modifying anti-rheumatic drugs, including methotrexate, leflunomide and sulfasalazine or tumor necrotizing factor-alpha blockades, were contraindicated due to drug eruption and a history of lung cancer.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Artritis Reumatoide
/
Sulfasalazina
/
Ácido Tranexámico
/
Prednisolona
/
Metotrexato
/
Interleucina-6
/
Tacrolimus
/
Erupciones por Medicamentos
/
Antirreumáticos
/
Síndrome de Activación Macrofágica
Límite:
Humanos
Idioma:
Inglés
Revista:
The Ewha Medical Journal
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS